Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Healthcare
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more

Recent & Breaking News (NYSE:TAK)

Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

Business Wire April 18, 2022

Takeda Announces Completion of Acquisition of Own Shares

Business Wire April 13, 2022

Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)

Business Wire April 12, 2022

Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners

Business Wire April 5, 2022

Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

Business Wire March 28, 2022

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

Business Wire February 28, 2022

Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2

Business Wire February 18, 2022

Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum

Business Wire February 3, 2022

FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)

Business Wire January 31, 2022

Takeda Named Global Top Employer for Fifth Consecutive Year

Business Wire January 19, 2022

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 10, 2022

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors

Business Wire January 10, 2022

Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721

Business Wire December 21, 2021

 Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021

Business Wire December 13, 2021

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY(TM) (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Business Wire December 8, 2021

Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting

Business Wire December 7, 2021

Takeda's LIVTENCITY(TM) (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States

Business Wire December 2, 2021

Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities

Business Wire November 30, 2021

Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies

Business Wire November 23, 2021

Canadian Blood Services Awards Takeda Canada Three-Year Tender for Hemophilia treatment ADYNOVATE®

PR Newswire November 17, 2021